Osteopenia: The Gray Zone Between Normal and Osteoporosis

What Osteopenia Is — and What It Is Not

Osteopenia is a term that describes bone mineral density (BMD) that is lower than normal peak bone mass but not low enough to meet the diagnostic threshold for osteoporosis. Specifically, it corresponds to a DXA T-score between -1.0 and -2.5. The term was introduced by the World Health Organization (WHO) in 1994 as part of a classification system intended for epidemiological research — it was designed to quantify the prevalence of low bone mass in populations, not necessarily to serve as a clinical diagnosis that triggers treatment in every individual.

This distinction matters. Being told you have osteopenia can feel alarming, as though you have a disease that requires immediate action. In reality, osteopenia is an extremely common finding — by definition, it encompasses a large portion of the population, particularly postmenopausal women. According to data from the National Health and Nutrition Examination Survey (NHANES), an estimated 43 million Americans over 50 have osteopenia, compared to approximately 10 million with osteoporosis. Osteopenia is a risk factor for fracture, but it is not, by itself, a disease that invariably requires pharmacological treatment.

The Population Paradox

One of the most counterintuitive facts about osteoporosis epidemiology is that the majority of fragility fractures occur in people with osteopenia, not osteoporosis. This is sometimes called the "prevention paradox" — because osteopenia is so much more prevalent than osteoporosis, even though the per-person fracture rate is lower, the sheer number of people in the osteopenic range means they contribute more total fractures to the population.

A study published in Osteoporosis International by Siris and colleagues, using data from the National Osteoporosis Risk Assessment (NORA), found that 82% of postmenopausal women who experienced a fracture during follow-up had T-scores above -2.5 — meaning they did not have osteoporosis by DXA criteria. This does not mean osteopenia is harmless, but it illustrates why bone density alone is an incomplete predictor of who will fracture.

Why Some People With Osteopenia Fracture and Others Do Not

If bone density alone does not determine fracture outcome, what does? The answer involves multiple factors that operate alongside BMD:

Bone Quality

DXA measures areal bone mineral density — the amount of mineral per unit area. It does not capture trabecular microarchitecture, cortical porosity, collagen integrity, microdamage accumulation, or bone geometry. Two individuals with identical T-scores can have very different bone quality and therefore very different fracture risk. Newer assessments such as trabecular bone score (TBS) attempt to capture some of this information, but they are not yet routinely available or incorporated into standard clinical practice.

Fall Risk

Most non-vertebral fractures in older adults result from falls. Factors that increase fall risk — including muscle weakness, poor balance, visual impairment, sedating medications, orthostatic hypotension, and environmental hazards — independently contribute to fracture probability, regardless of bone density. An individual with osteopenia who falls frequently may be at higher fracture risk than someone with osteoporosis who never falls.

Age

Fracture risk increases with age independently of bone density. A 75-year-old woman with a T-score of -1.5 has a substantially higher absolute fracture risk than a 55-year-old woman with the same T-score. This reflects cumulative changes in bone quality, muscle mass, neuromuscular function, and comorbidities that are not captured by the DXA number.

Clinical Risk Factors

Prior fragility fracture, parental hip fracture, glucocorticoid use, smoking, rheumatoid arthritis, excessive alcohol use, and secondary causes of bone loss all increase fracture risk independently of BMD. The FRAX tool integrates these factors with bone density to provide a more complete estimate of 10-year fracture probability.

The Clinical Decision: Monitor or Treat?

The central clinical question for individuals with osteopenia is whether to simply monitor bone density over time or to initiate pharmacological treatment. This is where the "gray zone" descriptor is most apt — there is no single right answer, and the decision depends on the individual's overall fracture risk profile.

When Monitoring May Be Appropriate

For many individuals with osteopenia — particularly younger postmenopausal women with T-scores closer to -1.0, no prior fractures, and few additional risk factors — the 10-year fracture risk is low enough that pharmacological treatment is unlikely to provide meaningful benefit relative to its cost and potential side effects. In this scenario, the evidence-based approach is:

• Ensure adequate calcium intake (1,000-1,200 mg/day from food plus supplements as needed) and vitamin D (600-800 IU/day, or more if deficient)
• Engage in regular weight-bearing and resistance exercise
• Address modifiable risk factors (smoking cessation, limiting alcohol, fall prevention measures)
• Repeat DXA at an interval appropriate to the baseline T-score — every 3-5 years for moderate osteopenia, potentially longer for mild osteopenia
• Calculate FRAX to quantify 10-year fracture risk and guide whether the monitoring strategy remains appropriate

When Treatment May Be Appropriate

For individuals with osteopenia whose overall fracture risk exceeds treatment thresholds, pharmacological intervention may be warranted even though they do not meet the DXA criteria for osteoporosis. In the United States, the Bone Health and Osteoporosis Foundation recommends considering treatment when:

• The FRAX 10-year probability of a major osteoporotic fracture is 20% or greater, or
• The FRAX 10-year probability of a hip fracture is 3% or greater

Scenarios where an individual with osteopenia might exceed these thresholds include: an older woman (age 75+) with a T-score of -2.0 and a prior fracture; a patient on long-term glucocorticoids with a T-score of -1.8; or a woman with a strong family history of hip fracture and multiple additional risk factors. In these cases, the total risk picture justifies treatment even though the T-score alone does not reach -2.5.

The Psychology of the Diagnosis

Research has shown that the label "osteopenia" can cause significant anxiety in patients, sometimes disproportionate to the actual clinical risk. A study published in the Journal of General Internal Medicine found that women who were told they had osteopenia reported increased worry about fractures and were more likely to perceive themselves as having a serious health condition, even when their absolute fracture risk was low.

This psychological impact is one reason why clear communication about what osteopenia means — and does not mean — is so important. Osteopenia is not a disease in the same sense as osteoporosis. It is a descriptor of where bone density falls on a continuum. For many people, it represents normal age-related bone loss that does not require medication. For others, it is a signal that, combined with additional risk factors, warrants closer attention.

Special Considerations

Premenopausal Women

In premenopausal women, the term "osteopenia" based on T-scores should not be used. The International Society for Clinical Densitometry (ISCD) recommends using Z-scores in this population, and the terminology "below the expected range for age" (Z-score equal to or below -2.0) or "within the expected range for age" is preferred. A low Z-score in a premenopausal woman should prompt investigation for secondary causes of bone loss rather than a reflexive diagnosis of osteopenia.

Men Under 50

Similarly, the WHO T-score classification was not originally intended for men under 50. The ISCD recommends Z-scores in this population, and the term "osteopenia" should be used cautiously. Low bone density in a younger man should trigger a workup for secondary causes, including hypogonadism, glucocorticoid excess, gastrointestinal diseases, and other conditions.

Patients With Diabetes

Type 2 diabetes presents a unique challenge in the context of osteopenia. Individuals with type 2 diabetes often have normal or even elevated BMD, yet they experience higher fracture rates than non-diabetic individuals. This discordance is thought to reflect impaired bone quality related to advanced glycation end products (AGEs), altered bone turnover, and possibly effects of diabetes medications. For diabetic patients with osteopenia, the actual fracture risk may be higher than the T-score suggests, and clinical judgment should account for this discrepancy.

Practical Takeaways

1. Osteopenia is common and often does not require medication. Most individuals with osteopenia will not fracture, and lifestyle measures are the appropriate first-line approach for many.
2. But osteopenia is not nothing. It indicates that bone density is below peak levels, and in the right clinical context (advanced age, prior fracture, multiple risk factors), it can signal meaningful fracture risk.
3. Use FRAX to move beyond the T-score. A FRAX calculation integrates bone density with clinical risk factors to provide a more actionable estimate of fracture probability.
4. Optimize the modifiable factors. Regardless of whether medication is prescribed, ensuring adequate calcium and vitamin D, engaging in regular weight-bearing exercise, and addressing fall risk are universally beneficial.
5. Follow up. Osteopenia warrants monitoring over time. Bone density can remain stable, improve, or continue to decline. Serial DXA scans at appropriate intervals help track the trajectory and inform ongoing management decisions.